ID: ALA440146

Max Phase: Preclinical

Molecular Formula: C39H45N3O6

Molecular Weight: 651.80

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCc1ccc(C(CCN2CCN(c3ccccc3OC)CC2)Oc2ccc(C(=O)Nc3ccccc3OCCCC(=O)O)cc2)cc1

Standard InChI:  InChI=1S/C39H45N3O6/c1-3-29-14-16-30(17-15-29)35(22-23-41-24-26-42(27-25-41)34-10-5-7-12-37(34)46-2)48-32-20-18-31(19-21-32)39(45)40-33-9-4-6-11-36(33)47-28-8-13-38(43)44/h4-7,9-12,14-21,35H,3,8,13,22-28H2,1-2H3,(H,40,45)(H,43,44)

Standard InChI Key:  FIBKNKOHOLWVRI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 651.80

Molecular Weight (Monoisotopic): 651.3308

AlogP: 7.09

#Rotatable Bonds: 16

Polar Surface Area: 100.57

Molecular Species: ACID

HBA: 7

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.90

CX Basic pKa: 7.92

CX LogP: 4.43

CX LogD: 4.34

Aromatic Rings: 4

Heavy Atoms: 48

QED Weighted: 0.12

Np Likeness Score: -0.99

References

1. Yoshida K, Horikoshi Y, Eta M, Chikazawa J, Ogishima M, Fukuda Y, Sato H..  (1998)  Synthesis of benzanilide derivatives as dual acting agents with alpha 1-adrenoceptor antagonistic action and steroid 5-alpha reductase inhibitory activity.,  8  (21): [PMID:9873656] [10.1016/s0960-894x(98)00538-1]

Source

Source(1):

• Scientific Literature